Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments

References

• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–516. doi:10.1016/j.jaad.2013.11.013
   PubMed Web of Science ®Google Scholar
• Langley RG, Daudén E. Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology. 2010;221(Suppl 1):29–42. doi:10.1159/000316179
   PubMedGoogle Scholar
• Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24:22–27. doi:10.1111/j.1468-3083.2009.03344.x
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–407. doi:10.1016/S0190-9622(99)70112-X
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Blome C, Schafer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580–585. doi:10.1111/j.1365-2133.2010.09831.x
   PubMed Web of Science ®Google Scholar
• Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27. doi:10.1016/j.jaad.2005.07.073
   PubMed Web of Science ®Google Scholar
• Pasch MC. Nail psoriasis: a review of treatment options. Drugs. 2016;76(6):675–705. doi:10.1007/s40265-016-0564-5
   PubMed Web of Science ®Google Scholar
• de Berker D. Management of nail psoriasis. Clin Exp Dermatol. 2000;25:357–362. doi:10.1046/j.1365-2230.2000.00663.x
   PubMed Web of Science ®Google Scholar
• McGonagle D, Ash Z, Dickie L, McDermott M, Aydin SZ. The early phase of psoriatic arthritis. Ann Rheum Dis. 2011;70(Suppl 1):i71–6. doi:10.1136/ard.2010.144097
   PubMed Web of Science ®Google Scholar
• McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal appendage-implications for an improved understanding of the link between psoriasis and arthritis. Dermatology. 2009;218(2):97–102. doi:10.1159/000182250
   PubMed Web of Science ®Google Scholar
• Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017;55(3):131–135. doi:10.5114/reum.2017.68912
   PubMedGoogle Scholar
• Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a questionnaire-based survey. Br J Dermatol. 2013;169(2):314–319. doi:10.1111/bjd.12354
   PubMed Web of Science ®Google Scholar
• Dogra S, Yadav S. Acitretin in psoriasis: an evolving scenario. Int J Dermatol. 2014;53(5):525–538. doi:10.1111/ijd.12365
   PubMed Web of Science ®Google Scholar
• Brazzelli V, Martinoli S, Prestinari F, Borroni G. An impressive therapeutic result of nail psoriasis to Acitretin. J Eur Acad Dermatol Venereol. 2004;18(2):229–230. doi:10.1111/j.1468-3083.2004.00667.x
   PubMed Web of Science ®Google Scholar
• Brazzelli V, Martinoli S, Prestinari F, Borroni G. Severe nail psoriasis with a rapid response to Acitretin. Clin Exp Dermatol. 2009;34(7):e332–e333. doi:10.1111/j.1365-2230.2009.03282.x
   PubMed Web of Science ®Google Scholar
• Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. Evaluation of the efficacy of Acitretin therapy for nail psoriasis. Arch Dermatol. 2009;145(3):269–271. doi:10.1001/archdermatol.2008.600
   PubMedGoogle Scholar
• Ricceri F, Pescitelli L, Tripo L, Bassi A, Prignano F. Treatment of severe nail psoriasis with Acitretin: an impressive therapeutic result. Dermatol Ther. 2013;26(1):77–78. doi:10.1111/j.1529-8019.2012.01539.x
   PubMed Web of Science ®Google Scholar
• Krajewska-Włodarczyk M, Żuber Z, Owczarczyk-Saczonek A. Ultrasound evaluation of the effectiveness of the use of acitretin in the treatment of nail psoriasis. J Clin Med. 2021;10(10):2122. doi:10.3390/jcm10102122
   PubMed Web of Science ®Google Scholar
• Graceffa D, Bonifati C, Pacifico A, Morrone A. When the old works better than the new: a case of severe nail psoriasis successfully treated with Acitretin after failure of two biologic regimens. Dermatol Ther. 2020;33(4):e13615. doi:10.1111/dth.13615
   PubMed Web of Science ®Google Scholar
• Mukai MM, Poffo IF, Werner B, Brenner FM, Lima Filho JH. NAPSI utilization as an evaluation method of nail psoriasis in patients using Acitretin. An Bras Dermatol. 2012;87(2):256–262. doi:10.1590/S0365-05962012000200010
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ruland V, Patsinakidis N, Luger TA. Use of methotrexate in patients with psoriasis. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S138–S144.
   PubMed Web of Science ®Google Scholar
• Gümüşel M, Özdemir M, Mevlitoğlu I, Bodur S. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one- blind, randomized study. J Eur Acad Dermatol Venereol. 2011;25(9):1080–1084. doi:10.1111/j.1468-3083.2010.03927.x
   PubMed Web of Science ®Google Scholar
• Tsiskarishvili NV, Katsitadze AG, Tsiskarishvili NI. Assessment of psoriatic nail lesions therapy by means of nail psoriasis severity index. Georgian Med News. 2011;199:43–47.
   Google Scholar
• Demirsoy EO, Kıran R, Salman S, et al. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. J Drugs Dermatol. 2013;12(9):1039–1043.
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016;43(2):356–361. doi:10.3899/jrheum.150614
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019;71(7):1112–1124. doi:10.1002/art.40851
   PubMed Web of Science ®Google Scholar
• Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10068):528–537. doi:10.1016/S0140-6736(16)32127-4
   PubMed Web of Science ®Google Scholar
• Drach M, Papageorgiou K, Maul JT, et al. Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). Arch Dermatol Res. 2019;311(10):753–760. doi:10.1007/s00403-019-01945-6
   PubMed Web of Science ®Google Scholar
• Lee JY. Severe 20-nail psoriasis successfully treated by low dose methotrexate. Dermatol Online J. 2009;15(11):8.
   Google Scholar
• Soleymani T, Vassantachart JM, Wu JJ. Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review. J Drugs Dermatol. 2016;15(3):293–301.
   PubMedGoogle Scholar
• Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg. 2004;8(2):122–125. doi:10.1177/120347540400800208
   PubMed Web of Science ®Google Scholar
• Karanikolas GN, Koukli EM, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol. 2011;38(11):2466–2474. doi:10.3899/jrheum.110242
   PubMed Web of Science ®Google Scholar
• Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernández M, Umbert-Millet P. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol. 2011;25(5):579–586. doi:10.1111/j.1468-3083.2010.03938.x
   PubMed Web of Science ®Google Scholar
• Balak DM. Fumaric acid esters in the management of psoriasis. Psoriasis Targets Ther. 2015;5:9–23. doi:10.2147/PTT.S51490
   PubMedGoogle Scholar
• Augustin M, Landeck L, Diemert S, et al. Long-term treatment with dimethyl fumarate for plaque psoriasis in routine practice: good overall effectiveness and positive effect on impactful areas. Dermatol Ther. 2022;12(5):1121–1131. doi:10.1007/s13555-022-00714-0
   Web of Science ®Google Scholar
• Vlachou C, Berth-Jones J. Nail psoriasis improvement in a patient treated with fumaric acid esters. J Dermatolog Treat. 2007;18(3):175–177. doi:10.1080/09546630701264331
   PubMed Web of Science ®Google Scholar
• Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol. 1980;116:1023–1024. doi:10.1001/archderm.1980.01640330061013
   PubMedGoogle Scholar
• Handfield-Jones SE, Boyle J, Harman RR. Local PUVA treatment for nail psoriasis. Br J Dermatol. 1987;116:280–281. doi:10.1111/j.1365-2133.1987.tb05834.x
   PubMed Web of Science ®Google Scholar
• Stern DK, Creasey AA, Quijije J, et al. UV-A and UV-B penetration of normal human cadaveric fingernail plate. Arch Dermatol. 2011;147(4):439–441. doi:10.1001/archdermatol.2010.375
   PubMedGoogle Scholar
• Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134–142. doi:10.1016/j.jaad.2015.09.001
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treat- ment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32(3):397–402. doi:10.1111/jdv.14738
   PubMed Web of Science ®Google Scholar
• Oak ASW, Ho-Pham H, Elewski BE. Improvement of 11 patients with nail psoriasis with apremilast: results of an investigator-initiated open-label study. J Am Acad Dermatol. 2020;83(6):1830–1832. doi:10.1016/j.jaad.2020.05.087
   PubMed Web of Science ®Google Scholar
• Muñoz-Santos C, Sola-Ortigosa J, Vidal D, Guilabert A. Apremilast improves quality of life and ultrasonography parameters in patients with nail psoriasis: a prospective cohort study. J Dermatol. 2021;48(10):1593–1596. doi:10.1111/1346-8138.16074
   PubMed Web of Science ®Google Scholar
• Magdaleno-Tapial J, Valenzuela-Oñate C, Ortiz-Salvador JM, Subiabre-Ferrer D, Hernández-Bel P. Effective treatment of nail psoriasis with apremilast: report of two cases and review of the literature. Dermatol Online J. 2018;24(9):13030/qt27x34947.
   Google Scholar
• Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168(5):1080–1087.
   PubMed Web of Science ®Google Scholar
• ENBREL. Etanercept (ENBREL) - Prescribing information; 1998. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf. Accessed July 10, 2023.
   Google Scholar
• Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009;23(8):896–904. doi:10.1111/j.1468-3083.2009.03211.x
   PubMed Web of Science ®Google Scholar
• Rallis E, Stavropoulou E, Rigopoulos D, et al. Rapid response of nail psoriasis to etanercept. J Rheumatol. 2008;35:544–545.
   PubMed Web of Science ®Google Scholar
• Barrera MV, Habicheyn S, Mendiola MV, et al. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol. 2008;18(6):683–687. doi:10.1684/ejd.2008.0541
   PubMed Web of Science ®Google Scholar
• Coelho JD, Diamantino F, Lestre S, et al. Treatment of severe nail psoriasis with etanercept. Indian J Dermatol Venereol Leprol. 2011;77(1):72–74. doi:10.4103/0378-6323.74996
   PubMed Web of Science ®Google Scholar
• Gomez VM, Navarra AR. Marked improvement in nail psoriasis during treatment with etanercept. Dermatol Ther. 2011;24(5):498–500. doi:10.1111/j.1529-8019.2012.01472.x
   PubMed Web of Science ®Google Scholar
• Niebel D, Wilsmann-Theis D, Wenzel J. Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept. J Dermatol. 2020;47(4):397–401. doi:10.1111/1346-8138.15222
   PubMed Web of Science ®Google Scholar
• Winterfield LS, Menter A. Infliximab. Dermatol Ther. 2004;17(5):409–426. doi:10.1111/j.1396-0296.2004.04044.x
   PubMedGoogle Scholar
• Bianchi L, Bergamin A, de Felice C, et al. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol. 2005;52(4):736–737. doi:10.1016/j.jaad.2004.09.012
   PubMed Web of Science ®Google Scholar
• Fabroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis.A retrospective study in 48 patients. J Eur Acad Dermatol Venereol. 2011;25(5):549–553. doi:10.1111/j.1468-3083.2010.03826.x
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol. 2008;159:453–456. doi:10.1111/j.1365-2133.2008.08686.x
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374. doi:10.1016/S0140-6736(05)67566-6
   PubMed Web of Science ®Google Scholar
• Saraceno R, Pietroleonardo L, Mazzotta A, Zangrilli A, Bianchi L, Chimenti S. TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis. Expert Opin Biol Ther. 2013;13(4):469–473. doi:10.1517/14712598.2013.736960
   PubMed Web of Science ®Google Scholar
• Safa G, Darrieux L. Dramatic response of nail psoriasis to infliximab. Case Rep Med. 2011;2011:107928. doi:10.1155/2011/107928
   PubMedGoogle Scholar
• Hussain W, Coulson I, Owen C. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clin Exp Dermatol. 2008;33:520–522. doi:10.1111/j.1365-2230.2008.02738.x
   PubMed Web of Science ®Google Scholar
• Satoh M, Yamamoto T. Case of recalcitrant nail psoriasis unresponsive to Adalimumab but successfully treated with infliximab. J Dermatol. 2017;44(11):e288–e289. doi:10.1111/1346-8138.13947
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomedicines. 2022;10(2):455. doi:10.3390/biomedicines10020455
   PubMed Web of Science ®Google Scholar
• Irla N, Yawalkar N. Marked improvement in nail psoriasis during treatment with Adalimumab. Dermatology. 2009;219(4):353–356. doi:10.1159/000252853
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with Adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol. 2010;24(5):530–534. doi:10.1111/j.1468-3083.2009.03453.x
   PubMed Web of Science ®Google Scholar
• Sola-Ortigosa J, Sanchez-Regana M, Umbert-Millet P. Efficacy of Adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice. J Dermatolog Treat. 2012;23(3):203–207. doi:10.3109/09546634.2010.519376
   PubMed Web of Science ®Google Scholar
• Paul C, van de Kerkhof P, Puig L, et al. Influence of psoriatic arthritis on the efficacy of Adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. Eur J Dermatol. 2012;22(6):762–769. doi:10.1684/ejd.2012.1863
   PubMed Web of Science ®Google Scholar
• Thaci D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015;29(2):353–360. doi:10.1111/jdv.12553
   PubMed Web of Science ®Google Scholar
• Elewski BE, Okun MM, Papp K, et al. Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2018;78(1):90–9. e1. doi:10.1016/j.jaad.2017.08.029
   PubMed Web of Science ®Google Scholar
• Elewski BE, Baker CS, Crowley JJ, et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2019;33(11):2168–2178. doi:10.1111/jdv.15793
   PubMed Web of Science ®Google Scholar
• Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147:429–436. doi:10.1001/archdermatol.2010.384
   PubMed Web of Science ®Google Scholar
• Kokolakis G, Bachmann F, Wolk K, Sabat R, Philipp S. Efficacy of adalimumab for nail psoriasis during 24 months of continuous therapy. Acta Derm Venereol. 2020;100(14):adv00214. doi:10.2340/00015555-3545
   PubMedGoogle Scholar
• Komatsu-Fujii T, Honda T, Otsuka A, Kabashima K. Improvement of nail lesions in a patient with psoriatic arthritis by switching the treatment from an anti-interleukin-17A antibody to an anti-tumor necrosis factor-α antibody. J Dermatol. 2019;46(5):e158–e160. doi:10.1111/1346-8138.14700
   PubMed Web of Science ®Google Scholar
• Komatsu-Fujii T, Honda T, Otsuka A, Kabashima K. Inverse responses of the skin and nail lesions of psoriatic arthritis to an anti-interleukin-17A antibody and an anti-tumor necrosis factor-α antibody. J Dermatol. 2019;46(11):e440–e441. doi:10.1111/1346-8138.15006
   PubMed Web of Science ®Google Scholar
• CIMZIA. Certolizumab pegol (CIMZIA) - Prescribing information; 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf. Accessed July 10, 2023.
   Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55. doi:10.1136/annrheumdis-2013-203696
   PubMed Web of Science ®Google Scholar
• Mazzeo M, Dattola A, Cannizzaro MV, Bianchi L. Nail psoriasis treated with certolizumab pegol in patients with psoriatic arthritis: preliminary observation. Actas Dermosifiliogr. 2019;110(2):169–171. doi:10.1016/j.ad.2018.02.010
   PubMed Web of Science ®Google Scholar
• Dattola A, Balato A, Megna M, et al. Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. J Eur Acad Dermatol Venereol. 2020;34(12):2839–2845. doi:10.1111/jdv.16606
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Asahina A, Imafuku S, et al. Efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: 52-week results. Dermatol Ther. 2021;11(3):943–960. doi:10.1007/s13555-021-00520-0
   Web of Science ®Google Scholar
• SIMPONI. Golimumab (SIMPONI) - Prescribing information; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf. Accessed July 10, 2023.
   Google Scholar
• Mease P, Elaine Husni M, Chakravarty SD, et al. Evaluation of improvement in skin and nail psoriasis in bio-na ̈ıve patients with active psoriatic arthritis treated with golimumab: results through week 52 of the GO-VIBRANT study. ACR Open Rheumatol. 2020;2(11):640–647. doi:10.1002/acr2.11180
   PubMedGoogle Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–986. doi:10.1002/art.24403
   PubMed Web of Science ®Google Scholar
• Vieira-Sousa E, Alves P, Rodrigues AM, et al. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of Golimumab plus methotrexate (MTX) versus placebo plus MTX in improving dactylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis. 2020;79:490–498. doi:10.1136/annrheumdis-2019-216500
   PubMedGoogle Scholar
• Jung SY. A case of nail psoriasis improved by treatment with golimumab in a psoriatic arthritis patient. Ann Dermatol. 2017;29(4):491–492. doi:10.5021/ad.2017.29.4.491
   PubMed Web of Science ®Google Scholar
• Martora F, Megna M, Battista T, et al. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023;16:135–148. doi:10.2147/CCID.S391356
   PubMed Web of Science ®Google Scholar
• Rallis E, Kintzoglou S, Verros C. Ustekinumab for rapid treatment of nail psoriasis. Arch Dermatol. 2010;146(11):1315–1316. doi:10.1001/archdermatol.2010.332
   PubMedGoogle Scholar
• Rigopoulos D, Gregoriou S, Makris M, et al. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology. 2011;223(4):325–329. doi:10.1159/000334482
   PubMed Web of Science ®Google Scholar
• Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, 51. nonrandomized study. J Dermatolog Treat. 2013;24:96–100. doi:10.3109/09546634.2011.607796
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in 52. Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39:242–252. doi:10.1111/j.1346-8138.2011.01347.x
   PubMed Web of Science ®Google Scholar
• Youn SW, Kim BR, Cho S, et al. Determination of the nail psoriasis severity index improvement rate standards for nail psoriasis treatment in a Phase IV clinical trial of ustekinumab: the MARCOPOLO study. J Eur Acad Dermatol Venereol. 2017;31(6):e298–e299. doi:10.1111/jdv.14083
   PubMed Web of Science ®Google Scholar
• Yang S, Kim BR, Kim M, Youn SW. Toenail Psoriasis during Ustekinumab Therapy: results and Limitations. Ann Dermatol. 2021;33(2):131–137. doi:10.5021/ad.2021.33.2.131
   PubMed Web of Science ®Google Scholar
• Conrad C, Ortmann CE, Vandemeulebroecke M, Kasparek T, Reich K. Nail involvement as a predictor of differential treatment effects of secukinumab versus ustekinumab in patients with moderate to severe psoriasis. Dermatol Ther. 2022;12(1):233–241. doi:10.1007/s13555-021-00654-1
   Web of Science ®Google Scholar
• Bagel J, Nia J, Hashim PW, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther. 2018;8:571–579. doi:10.1007/s13555-018-0265-y
   PubMed Web of Science ®Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–9.ù. doi:10.1016/j.jaad.2015.05.013
   PubMed Web of Science ®Google Scholar
• Vitiello M, Tosti A, Abuchar A, Zaiac M, Kerdel FA. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients. Int J Dermatol. 2013;52(3):358–362. doi:10.1111/j.1365-4632.2011.05320.x
   PubMed Web of Science ®Google Scholar
• Byun SY, Kim BR, Choi JW, Youn SW. Severe nail fold psoriasis extending from nail psoriasis resolved with ustekinumab: suggestion of a cytokine overflow theory in the nail unit. Ann Dermatol. 2016;28(1):94–97. doi:10.5021/ad.2016.28.1.94
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35(9):e15667. doi:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Marasca C, Fornaro L, Martora F, Picone V, Fabbrocini G, Megna M. Onset of vitiligo in a psoriasis patient on ixekizumab. Dermatol Ther. 2021;34(5):e15102. doi:10.1111/dth.15102
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–1199. doi:10.1056/NEJMoa1109997
   PubMed Web of Science ®Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (Adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79–87. doi:10.1136/annrheumdis-2016-209709
   PubMed Web of Science ®Google Scholar
• Wasel N, Thaçi D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head- to-head study (IXORA-S). Dermatol Ther. 2020;10:663–670. doi:10.1007/s13555-020-00383-x
   PubMed Web of Science ®Google Scholar
• Leonardi C, Reich K, Foley P, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 Phase- 3 randomized controlled trials. Dermatol Ther. 2020;10:431–447. doi:10.1007/s13555-020-00367-x
   PubMed Web of Science ®Google Scholar
• van de Kerkhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(3):477–482. doi:10.1111/jdv.14033
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, et al. A head-to- head comparison of the efficacy and safety of ixekizumab and Adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–131.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi C, Elewski B, et al. A head-to- head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–1358. doi:10.1111/bjd.18851
   PubMed Web of Science ®Google Scholar
• Egeberg A, Kristensen LE, Vender R, et al. Sustained resolution of nail psoriasis through 5 years with ixekizumab: a post-hoc analysis from UNCOVER-3. Acta Derm Venereol. 2022;102:adv00787. doi:10.2340/actadv.v102.2269
   PubMed Web of Science ®Google Scholar
• Elewski BE, Blauvelt A, Gallo G, et al. Simultaneous nail and skin clearance in ixekizumab head-to-head trials for moderate-to-severe psoriasis and psoriatic arthritis. Dermatol Ther. 2022;12(4):911–920. doi:10.1007/s13555-022-00704-2
   Web of Science ®Google Scholar
• Barešić M, Smiljanić Tomičević L, Anić B, Mayer M. Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review. Rheumatol Int. 2022;42(2):365–370. doi:10.1007/s00296-021-05065-1
   PubMed Web of Science ®Google Scholar
• COSENTIX. Secukinumab (COSENTIX) - Prescribing information; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125504s043lbl.pdf. Accessed July 10, 2023.
   Google Scholar
• Pistone G, Gurreri R, Tilotta G, Castelli E, Bongiorno MR. Secukinumab efficacy in the treatment of nail psoriasis: a case series. J Dermatolog Treat. 2018;29(sup1):21–24. doi:10.1080/09546634.2018.1529381
   PubMed Web of Science ®Google Scholar
• Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954–966. doi:10.1111/bjd.17351
   PubMed Web of Science ®Google Scholar
• Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425–436. doi:10.1111/bjd.19262
   PubMed Web of Science ®Google Scholar
• Nash P, Mease PJ, Kirkham B, et al. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study. Clin Exp Rheumatol. 2022;40(5):952–959. doi:10.55563/clinexprheumatol/3nuz51
   PubMed Web of Science ®Google Scholar
• He F, Long FY, Zhang ZQ, Xia RY, Lu Y, Yin ZQ. Intramatricial injection of anti-interleukin-17A antibody for six patients with nail psoriasis. Clin Exp Dermatol. 2022;47(2):432–433. doi:10.1111/ced.14933
   PubMed Web of Science ®Google Scholar
• Gregoriou S, Tsiogka A, Tsimpidakis A, Nicolaidou E, Kontochristopoulos G, Rigopoulos D. Treatment of nail psoriasis with brodalumab: an open-label unblinded study. J Eur Acad Dermatol Venereol. 2021;35:e299–301. doi:10.1111/jdv.17055
   PubMed Web of Science ®Google Scholar
• Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38–48. doi:10.1016/S0140-6736(22)02303-0
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45:1053–1062. doi:10.1111/1346-8138.14504
   PubMed Web of Science ®Google Scholar
• Gerdes S, Asadullah K, Hoffmann M, et al. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. J Eur Acad Dermatol Venereol. 2022;36(9):1568. doi:10.1111/jdv.18218
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225–231. doi:10.1136/annrheumdis-2021-221019
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Ismail FF, May J, Moi J, Sinclair R. Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment. Dermatol Ther. 2020;33(2):e13216. doi:10.1111/dth.13216
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11(9):2631. doi:10.3390/jcm11092631
   PubMed Web of Science ®Google Scholar
• Brunasso A. Nail psoriasis improvement during tildrakizumab therapy: a real-life experience. J Drugs Dermatol. 2022;21(8):914–916. doi:10.36849/JDD.6828
   PubMed Web of Science ®Google Scholar
• Tham SN, Lim JJ, Tay SH, et al. Clinical observations on nail changes in psoriasis. Ann Acad Med Singapore. 1988;17:482–485.
   PubMedGoogle Scholar
• Puri N, Mahajan BB. Nail changes in psoriasis – a profile. J Pak Assoc Dermatol. 2011;21:165–169.
   Google Scholar
• Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. J Am Acad Dermatol. 2019;81(1):228–240. doi:10.1016/j.jaad.2019.01.072
   PubMed Web of Science ®Google Scholar
• Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: a controlled double- blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol. 1998;139(4):655–659. doi:10.1046/j.1365-2133.1998.02462.x
   PubMed Web of Science ®Google Scholar
• de Jong EM, Menke HE, van Praag MC, van De Kerkhof PC. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-en- hancing vehicle: a double-blind study. Dermatology. 1999;199(4):313–318. doi:10.1159/000018281
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol. 1998;25(4):231–233. doi:10.1111/j.1346-8138.1998.tb02386.x
   PubMedGoogle Scholar
• Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double- blind, randomized, vehicle-controlled study. Cutis. 2001;68(5):355–358.
   PubMed Web of Science ®Google Scholar
• Cannavo SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology. 2003;206(2):153–156. doi:10.1159/000068469
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338–341. doi:10.1159/000202179
   PubMed Web of Science ®Google Scholar
• Balbás GM, Regaña MS, Millet PU. Tacalcitol ointment for the treatment of nail pso- riasis. J Dermatolog Treat. 2009;20(5):308–310. doi:10.1080/09546630902787585
   PubMed Web of Science ®Google Scholar
• Saleem K, Azim W. Treatment of nail psoriasis with a modified regimen of steroid injections. J Coll Physicians Surg Pak. 2008;18(2):78–81.
   PubMed Web of Science ®Google Scholar
• Choudhary P, Mehta RD, Ghiya BC, Sharma D. Treatment of nail psoriasis with intramatrical methotrexate: an uncontrolled prospective study of 20 patients. J Am Acad Dermatol. 2021;84(2):526–528. doi:10.1016/j.jaad.2020.04.159
   PubMed Web of Science ®Google Scholar
• Mittal J, Mahajan B. Intramatricial injections for nail psoriasis: an open-label comparative study of triamcinolone, methotrexate, and cyclosporine. Indian J Dermatol Venereol Leprol. 2018;84(4):419. doi:10.4103/ijdvl.IJDVL_73_16
   PubMed Web of Science ®Google Scholar
• Grover C, Daulatabad D, Singal A. Role of nail bed methotrexate injections in isolated nail psoriasis: conventional drug via an unconventional route. Clin Exp Dermatol. 2017;42(4):420–423. doi:10.1111/ced.13087
   PubMed Web of Science ®Google Scholar
• Clark A, Jellinek NJ. Intralesional injection for inflammatory nail diseases. Dermatol Surg. 2016;42(2):257–260. doi:10.1097/DSS.0000000000000621
   PubMed Web of Science ®Google Scholar
• SILIQ. Brodalumab (SILIQ) Prescribing information; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf. Accessed July 10, 2023.
   Google Scholar
• Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatol Treat. 2020;2022:1–5.
   Google Scholar
• Pinter A, Bonnekoh B, Hadshiew IM, Zimmer S. Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. Clin Cosmet Investig Dermatol. 2019;12:509–517. doi:10.2147/CCID.S211938
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation [published online ahead of print, 2023 Jun 19]. Expert Opin Drug Saf. 2023;1–8. doi:10.1080/14740338.2023.2218086
   PubMed Web of Science ®Google Scholar
• TREMFYA. Guselkumab (TREMFYA) Prescribing information; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s007lbl.pdf. Accessed July 10, 2023.
   Google Scholar
• Foley P, Gordon K, Griffiths CEM, et al. Efficacy of guselkumab compared with Adalimumab and placebo for psoriasis in specific body regions. JAMA Dermatol. 2018;154(6):676–683. doi:10.1001/jamadermatol.2018.0793
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22(12):1431–1433. doi:10.1080/14712598.2022.2113872
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–2820. doi:10.1080/09546634.2022.2081655
   PubMed Web of Science ®Google Scholar
• Machado Á, Torres T. Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis Targets Ther. 2018;8:83–92. doi:10.2147/PTT.S165943
   PubMed Web of Science ®Google Scholar
• AbbVie. Skyrizi® (risankizumab-rzaa) injection, for subcutaneous use: US prescribing information; 2019. Available from: http://www.rxabbvie.com. Accessed April 20, 2022.
   Google Scholar
• Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658. doi:10.2147/CCID.S364640
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Soliman AM, Papp K, et al. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. J Eur Acad Dermatol Venereol. 2022;36(5):e389–e392. doi:10.1111/jdv.17931
   PubMed Web of Science ®Google Scholar
• AlAjlan A, Qasim R, AlTassan F, Qadoumi T, AlKaff T. A case of nail psoriasis improved with treatment by risankizumab. Oxf Med Case Rep. 2022;2022(11):omac127. doi:10.1093/omcr/omac127
   PubMed Web of Science ®Google Scholar
• ILUMYA. Tildrakizumab (ILUMYA) Prescribing information; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf. Accessed July 10, 2023.
   Google Scholar
• Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) Br. J Dermatol. 2020;182:605–617.
   Web of Science ®Google Scholar
• Simpson K, Low ZM, Howard A, Kern JS. Successful management of treatment resistant nail psoriasis with tildrakizumab. Australas J Dermatol. 2021;62(3):390–393.
   PubMed Web of Science ®Google Scholar
• Canal-García E, Bosch-Amate X, Belinchón I, Puig L. Nail Psoriasis. Psoriasis ungueal. Actas Dermosifiliogr. 2022;113(5):481–490. doi:10.1016/j.ad.2022.01.006
   PubMedGoogle Scholar
• Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;22(12):1503–1520. doi:10.1080/14712598.2022.2089020
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023;22(1):25–41. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023;22(1):43–58. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280–2282. doi:10.1111/ced.15336
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics. Clin Exp Dermatol. 2022;47(12):2310–2312. doi:10.1111/ced.15395
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2023;22(1):32–33. doi:10.1111/jocd.15414
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Fabbrocini G, Ruggiero A. Strategies adopted in a southern Italian referral centre to reduce Adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’. Clin Exp Dermatol. 2022;47(10):1864–1865. doi:10.1111/ced.15291
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Nappa P, Megna M. Reply to ‘Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2’ by Solimani et al. J Eur Acad Dermatol Venereol. 2022;36(10):e750–e751. doi:10.1111/jdv.18302
   PubMed Web of Science ®Google Scholar
• Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–479. doi:10.1038/s41584-022-00798-0
   PubMed Web of Science ®Google Scholar
• Reich K, Conrad C, Kristensen LE, et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J Dermatolog Treat. 2022;33(3):1652–1660. doi:10.1080/09546634.2021.1892024
   PubMed Web of Science ®Google Scholar